Plasma antithrombin III activity in normal pregnancy

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Pharmacology

Background:

• Thromboembolic phenomena incidence rises during pregnancy.
• Antithrombin III (ATIII) is investigated for its role in estrogen-induced thrombosis.
• Previous studies suggested a link between ATIII and thromboembolism in women using exogenous estrogens.

Purpose of the Study:

• To investigate the changes in antithrombin III activity during normal pregnancy and oral contraceptive use.
• To determine if decreased antithrombin III activity contributes to increased thromboembolic phenomena in these physiological and pharmacological states.

Main Methods:

• A plasma-based assay was utilized to measure antithrombin III activity.
• Patient groups included normal obstetric, postpartum, and oral contraceptive users.
• Comparative analysis of ATIII activity was performed within and among these groups.

Main Results:

• No statistically significant alterations in antithrombin III activity were observed in pregnant or postpartum women.
• Antithrombin III activity remained stable in women using oral contraceptives.
• The study found no significant differences in ATIII activity across the studied groups.

Conclusions:

• Decreased antithrombin III activity is unlikely to be the cause of increased thromboembolic phenomena during normal pregnancy.
• Oral contraceptive use does not appear to significantly impact antithrombin III activity in a way that promotes thromboembolism.
• Findings do not support the hypothesis that changes in ATIII are responsible for heightened thrombotic risk in these populations.